Related Experiment Videos
Molecular mechanisms of antisense drugs: RNase H
1Isis Pharmaceuticals, Inc., Carlsbad, CA 92008, USA.
Antisense & Nucleic Acid Drug Development
|May 21, 1998
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The concept and application of antisense oligonucleotides.
Diseases of the colon and rectum·2001
Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration.
Biochemical pharmacology·2001
Investigating the structure of human RNase H1 by site-directed mutagenesis.
The Journal of biological chemistry·2001
Variations in mRNA content have no effect on the potency of antisense oligonucleotides.
Antisense & nucleic acid drug development·2001
Human RNase III is a 160-kDa protein involved in preribosomal RNA processing.
The Journal of biological chemistry·2000
Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
Antisense & nucleic acid drug development·2003
Safety of CpG oligodeoxynucleotides in veterinary species.
Antisense & nucleic acid drug development·2003
Coupling of RNAi-mediated target downregulation with gene replacement.
Antisense & nucleic acid drug development·2003
Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells.
Antisense & nucleic acid drug development·2003
Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.
Antisense & nucleic acid drug development·2003
Effects of base modifications on antisense properties of 2'-O-methoxyethyl and PNA oligonucleotides.
Antisense & nucleic acid drug development·2003
Development of a rapid colorimetric method for detection of synthetic corticosteroids in food and dietary supplements.
Analytical methods : advancing methods and applications·2026
Predominant α₂-adrenoceptor control of chelonian systemic resistance arteries provides a mechanistic basis for the cardiovascular effects of α₂-agonist sedation.
American journal of physiology. Heart and circulatory physiology·2026
Management of erectile dysfunction in phosphodiesterase type 5 inhibitor nonresponders.
Current opinion in urology·2026